Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6875872 | ASTRAZENECA LP | Compounds |
May, 2014
(9 years ago) | |
US5900424 | ASTRAZENECA LP | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
US7411070 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(5 years ago) | |
US6369085 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5877192 | ASTRAZENECA LP | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
May, 2014
(9 years ago) | |
US5690960 | ASTRAZENECA LP | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
US6875872 (Pediatric) | ASTRAZENECA LP | Compounds |
Nov, 2014
(9 years ago) | |
US5877192 (Pediatric) | ASTRAZENECA LP | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
Nov, 2014
(9 years ago) | |
US5714504 | ASTRAZENECA LP | Compositions |
Feb, 2015
(9 years ago) | |
US5690960 (Pediatric) | ASTRAZENECA LP | Pharmaceutical formulation of omeprazole |
May, 2015
(8 years ago) | |
US5714504 (Pediatric) | ASTRAZENECA LP | Compositions |
Aug, 2015
(8 years ago) | |
US5900424 (Pediatric) | ASTRAZENECA LP | Omeprazole magnesium salt form |
Nov, 2016
(7 years ago) | |
US7411070 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
US6369085 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
US6428810 | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
US6428810 (Pediatric) | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
May, 2020
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
RTO(RTO) | Mar 28, 2017 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 28 March, 2014
Treatment: Treatment of frequent heartburn by administering a gastric acid reducer; Method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed; Method of treating fre...
Dosage: TABLET, DELAYED RELEASE;ORAL